{"filing":{"accession_number":"0001193125-26-335039","cik":"0001628171","ticker":"RVMDW","company_name":"Revolution Medicines, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"rvmd-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526335039/rvmd-20260805.htm"},"events":[{"id":24719,"run_id":22414,"accession_number":"0001193125-26-335039","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses financial results including R\u0026D expenses of $394.9M, G\u0026A expenses of $110.2M, and net loss of $644.4M for the quarter, along with cash position of $3.9B and updated full-year 2026 operating expense guidance of $2.1–$2.2B. The filing includes the full press release as Exhibit 99.1, which is the standard format for earnings disclosures.","company_name":"Revolution Medicines, Inc.","ticker":"RVMDW","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25373,"accession_number":"0001193125-26-335039","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses financial results including R\u0026D expenses of $394.9M, G\u0026A expenses of $110.2M, and net loss of $644.4M for the quarter, along with cash position of $3.9B and updated full-year 2026 operating expense guidance of $2.1–$2.2B. The filing includes the full press release as Exhibit 99.1, which is the standard format for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:15:55.560643+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25373,"accession_number":"0001193125-26-335039","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses financial results including R\u0026D expenses of $394.9M, G\u0026A expenses of $110.2M, and net loss of $644.4M for the quarter, along with cash position of $3.9B and updated full-year 2026 operating expense guidance of $2.1–$2.2B. The filing includes the full press release as Exhibit 99.1, which is the standard format for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:15:55.560643+00:00","company_name":"Revolution Medicines, Inc.","ticker":"RVMDW","filing_date":"2026-08-05"}]}